Navigation Links
Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Date:2/26/2008

EAST SETAUKET, N.Y., Feb. 26 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT:OB) and its collaborator, the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), reported at the 1st International Conference on Drug Discovery and Development, Dubai, UAE, February 6, 2008, that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against medulloblastoma cells growing in culture and in a mouse model of cancer. Medulloblastoma is the most common brain tumor of children and is often fatal.

Dr. John S. Kovach, the lead presenter and President and CEO of Lixte, said that the company and SNB, NINDS are continuing to develop LB-1 and other compounds for the treatment of human brain cancers. Brain cancers pose a particular challenge to the development of effective drug treatments. The brain is protected by a physiological barrier which prevents the entry of most potentially effective therapeutic agents. To be effective, drugs must be designed either to pass this barrier or to be administered directly into the brain. "Lixte is pursuing both strategies to deliver its lead compounds to brain cancers," said Dr. Kovach.

In other studies done by Lixte independently of NIH, Dr. Kovach commented, "That LB-1 and other lead compounds have also been found to have anti-cancer activity against a broad range of common human cancers growing in cell culture. The effectiveness of these compounds will now be determined in mouse models of human cancer, starting with lung and pancreatic cancer."

In addition, Dr. Kovach said that, "Some of Lixte's compounds have been shown to have anti-fungal activity. We have found that LB-2.1 and other drugs in a second series of patent-pending proprietary compounds inhibit the growth of several types of fungi that cause life-threatening infections in immuno- compromi
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Opportunities to Invest in Puerto Rico as Global Center for Biotechnology
2. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
3. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
5. Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Biotechnology Builds a New Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... More scientific research into the metabolism of stromal support ... the metabolism of these cell types in the development ... diabetes, inflammatory conditions and cancer. That was the conclusion ... KU Leuven in the leading journal Nature . ... sort of wake-up call. The metabolism of cancer cells ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... and extinctions around the world have been linked ... new research from the National Institute for Mathematical ... ranavirus, may also contribute. , In a ... which causes severe hemorrhage of internal organs in ... wood frogs if they are exposed to the ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... among those who apply the chemicals, study shows , ... pesticides have double the normal risk of developing a ... (monoclonal gammopathy of undetermined significance) and characterized by an ... monitoring because it can lead to multiple myeloma, a ...
... of Facebook, Twitter coincides with 30% drop in hours spent ... American kids and their parents are now spending more hours ... eroding the amount of time families spend together. , That,s ... week that families interact as group has fallen by nearly ...
... Power Plate(R) North America (PPNA), the global ... trend in fitness and beauty to the greater Los ... studio opening this month for the summer in Brentwood, ... machines, "Power Plate(R) - The Experience" will provide group ...
... stay up at night worrying whether they are going to develop ... and middle age is a lifetime away. As ... Feinberg School of Medicine have found that young adults (18 to ... a treadmill test -- are two to three times more likely ...
... scientists are among a multinational collaborative group to have ... European Union. The research will focus on ... common to all solid tumours. Hypoxia causes a ... resistant to radiotherapy and most forms of chemotherapy; as ...
... June 18 George Dahlman, senior vice president of ... testified today before the U.S. Senate Subcommittee on Defense ... cancer research program at the Department of Defense (DoD). ... determined that several blood cancers, including chronic lymphocytic leukemia ...
Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Surging Internet Use Cutting Into Family Time 2Health News:Surging Internet Use Cutting Into Family Time 3Health News:Power Plate(R) Opens Cutting-Edge Studio in L.A. 2Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:$16.8 million study will breathe new life into cancer battle 2Health News:The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 2
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing....
... UltraFit PK System rede phines sharpness ... trephine program for penetrating keratoplasty. Advanced ... cutting edge to achieve the critical fit ... disposable and fully customized system enables surgeons ...
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease....
Medicine Products: